| Rose-krystel Hegngi, MD | |
|
100 Frist Ct, Columbus, GA 31909-3578 | |
| (706) 494-2100 | |
| Not Available |
| Full Name | Rose-krystel Hegngi |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 100 Frist Ct, Columbus, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366902215 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 92308 (Georgia) | Primary |
| Entity Name | Emergency Group Of Columbus Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316458227 PECOS PAC ID: 2668735515 Enrollment ID: O20180406001191 |
News Archive
Osteoporosis Canada congratulates the Ontario government, the New Brunswick government, the Saskatchewan government and the British Columbia government for providing access to a new osteoporosis medication. Aclasta (zoledronic acid) is now available on public and private drug plans in Ontario, BC, SK, and NB meaning Canadians at high risk for fractures have access to increased treatment options.
Neuros Medical, Inc., a medical device company, announced promising results today from their recently completed feasibility study. The study was the first human test of the Company's patented high frequency Electrical Nerve Block™ technology and focused on patients with chronic amputation pain which affects nearly one million patients in the U.S. During the study, four of the five patients reported their pain was reduced to zero.
After early reports of microplastic pollution in our oceans and beaches sounded the alarm, the global scientific community intensified its focus into this area.
Low doses of metformin, a widely used diabetes medication, and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, a Purdue University study finds.
Results from a new major diabetes eye health study may have the potential to change the way vision loss due to diabetic macular edema, a serious and devastating complication of diabetes, is treated. One year results from the RESTORE study show that 37 per cent of patients treated with ranibizumab only and 43 per cent of those treated with ranibizumab plus laser therapy, had a significant improvement in visual acuity of 10 letters or more on an eye chart, compared to 16 per cent of patients treated with laser alone - the current standard treatment for visual impairment due to DME.
› Verified 2 days ago
| Entity Name | Heritage Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003321969 PECOS PAC ID: 6305100850 Enrollment ID: O20180509000280 |
News Archive
Osteoporosis Canada congratulates the Ontario government, the New Brunswick government, the Saskatchewan government and the British Columbia government for providing access to a new osteoporosis medication. Aclasta (zoledronic acid) is now available on public and private drug plans in Ontario, BC, SK, and NB meaning Canadians at high risk for fractures have access to increased treatment options.
Neuros Medical, Inc., a medical device company, announced promising results today from their recently completed feasibility study. The study was the first human test of the Company's patented high frequency Electrical Nerve Block™ technology and focused on patients with chronic amputation pain which affects nearly one million patients in the U.S. During the study, four of the five patients reported their pain was reduced to zero.
After early reports of microplastic pollution in our oceans and beaches sounded the alarm, the global scientific community intensified its focus into this area.
Low doses of metformin, a widely used diabetes medication, and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, a Purdue University study finds.
Results from a new major diabetes eye health study may have the potential to change the way vision loss due to diabetic macular edema, a serious and devastating complication of diabetes, is treated. One year results from the RESTORE study show that 37 per cent of patients treated with ranibizumab only and 43 per cent of those treated with ranibizumab plus laser therapy, had a significant improvement in visual acuity of 10 letters or more on an eye chart, compared to 16 per cent of patients treated with laser alone - the current standard treatment for visual impairment due to DME.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rose-krystel Hegngi, MD 100 Frist Ct, Columbus, GA 31909-3578 Ph: (706) 494-2100 | Rose-krystel Hegngi, MD 100 Frist Ct, Columbus, GA 31909-3578 Ph: (706) 494-2100 |
News Archive
Osteoporosis Canada congratulates the Ontario government, the New Brunswick government, the Saskatchewan government and the British Columbia government for providing access to a new osteoporosis medication. Aclasta (zoledronic acid) is now available on public and private drug plans in Ontario, BC, SK, and NB meaning Canadians at high risk for fractures have access to increased treatment options.
Neuros Medical, Inc., a medical device company, announced promising results today from their recently completed feasibility study. The study was the first human test of the Company's patented high frequency Electrical Nerve Block™ technology and focused on patients with chronic amputation pain which affects nearly one million patients in the U.S. During the study, four of the five patients reported their pain was reduced to zero.
After early reports of microplastic pollution in our oceans and beaches sounded the alarm, the global scientific community intensified its focus into this area.
Low doses of metformin, a widely used diabetes medication, and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, a Purdue University study finds.
Results from a new major diabetes eye health study may have the potential to change the way vision loss due to diabetic macular edema, a serious and devastating complication of diabetes, is treated. One year results from the RESTORE study show that 37 per cent of patients treated with ranibizumab only and 43 per cent of those treated with ranibizumab plus laser therapy, had a significant improvement in visual acuity of 10 letters or more on an eye chart, compared to 16 per cent of patients treated with laser alone - the current standard treatment for visual impairment due to DME.
› Verified 2 days ago
Dr. Jonathan Thomas, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 8400 Veterans Pkwy Apt 814, Columbus, GA 31909 Phone: 814-504-4211 | |
Dr. Jacqueline Akua Owusu, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2022 10th Ave Ste B, Columbus, GA 31901 Phone: 706-507-9407 Fax: 706-507-9408 | |
Mr. David P. Smith, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2122 Manchester Expressway, Columbus, GA 31904 Phone: 706-596-4000 | |
John R Corbin, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2122 Manchester Expressway, Columbus, GA 31904 Phone: 706-596-4000 | |
Dr. Kennon A Mclendon, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 710 Center St, Columbus, GA 31901 Phone: 706-571-1200 | |
Michael David Hagues, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2122 Manchester Expressway, Columbus, GA 31904 Phone: 706-596-4000 | |
Gehrig Leonard Harris Jr., M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7093 Haddonfield Ct, Columbus, GA 31904 Phone: 337-336-0423 |